Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering

Core Viewpoint - Sharp Therapeutics Corp. has successfully closed the first tranche of its non-brokered private placement for unsecured convertible notes, raising a total of US$500,000 through the issuance of 500 notes, with proceeds allocated for general working capital purposes [1]. Group 1: Note Offering Details - Each note has a principal amount of US$1,000 and is convertible into common shares at a price of US$2.00 per share, with a conversion option available until 12 months post-closing [2]. - The notes carry an interest rate of 6.0% per annum, calculated as simple interest and payable in cash on the maturity date [3]. - The first tranche included participation from insiders, with STX Partners, LLC acquiring 200 notes for US$200,000, Newlin Investment Company 1, LLC acquiring 100 notes for US$100,000, and others, totaling 350 notes for US$350,000 [4]. Group 2: Regulatory and Compliance Information - The insider participation in the first tranche is classified as a related-party transaction, exempt from formal valuation or minority shareholder approval under Multilateral Instrument 61-101, as the transaction does not exceed 25% of the company's market capitalization [5]. - The company did not file a material change report prior to the closing due to the timing of insider participation details, and no new Control Person will be created as a result of this tranche [6]. Group 3: Future Commitments and Offerings - STX has committed an additional US$800,000 for future contributions in four tranches of US$200,000 each, scheduled for March and April 2026 [7]. - The notes were offered through private placement in Canada and the United States, adhering to applicable exemptions from prospectus requirements [8]. Group 4: Company Overview - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines high throughput screening technologies and computationally optimized compound libraries [10].